ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(27), P. 18046 - 18057
Published: June 27, 2024
Tumor
metastasis
remains
a
major
challenge
in
cancer
management.
Among
various
treatment
strategies,
immune
cell-based
therapy
holds
great
potential
for
inhibiting
metastasis.
However,
its
wide
application
is
restricted
by
complex
preparations,
as
well
inadequate
homing
and
controllability.
Herein,
we
present
groundbreaking
approach
bioorthogonally
manipulating
tumor-NK
(natural
killer)
cell
assembly
to
inhibit
tumor
Multiple
dibenzocyclootyne
(DBCO)
groups
decorated
long
single-stranded
DNA
were
tail-modified
on
core–shell
upconversion
nanoparticles
(CSUCNPs)
condensed
photosensitive
chemical
linker
(PC-Linker)
shield
most
of
the
DBCO
groups.
On
one
hand,
light-triggered
scaffolds
formed
cross-linked
network
click
chemistry,
effectively
impeding
migration.
other
efficient
cellular
facilitated
effective
communication
between
cells
NK-92
cells,
leading
enhanced
response
against
tumors
further
suppression
These
features
make
our
strategy
highly
applicable
range
metastatic
cancers.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(30)
Published: May 4, 2024
Abstract
Low
efficacy
of
immunotherapy
due
to
the
poor
immunogenicity
most
tumors
and
their
insufficient
infiltration
by
immune
cells
highlights
importance
inducing
immunogenic
cell
death
activating
system
for
achieving
better
treatment
outcomes.
Herein,
ferroelectric
Bi
2
CuO
4
nanoparticles
with
rich
copper
vacancies
(named
BCO‐V
Cu
)
are
rationally
designed
engineered
ferroelectricity‐enhanced
apoptosis,
cuproptosis,
subsequently
evoked
immunotherapy.
In
this
structure,
suppressed
recombination
electron–hole
pairs
band
bending
polarization
lead
high
catalytic
activity,
triggering
reactive
oxygen
species
bursts
apoptosis.
The
fragments
produced
apoptosis
serve
as
antigens
activate
T
cells.
Moreover,
generated
charge
catalysis,
nanomedicine
can
act
“a
smart
switch”
open
membrane,
promote
nanomaterial
endocytosis,
shut
down
+
outflow
pathway
evoke
thus
a
strong
response
is
triggered
reduced
content
adenosine
triphosphate.
Ribonucleic
acid
transcription
tests
reveal
pathways
related
activation.
Thus,
study
firstly
demonstrates
feasible
strategy
enhancing
using
single
semiconductor‐induced
cuproptosis.
Scientific Reports,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Oct. 25, 2024
Accumulating
research
showed
that
ENC1
plays
a
critical
role
in
maintaining
the
physiological
functions.
However,
little
is
known
about
its
predicting
prognosis
and
immunotherapy
response
across
cancers.
In
our
results,
compared
to
normal
tissues,
most
cancer
tissues
exhibit
increased
expression.
We
found
common
type
of
genetic
variation
was
gene
mutation.
addition,
positive
correlation
between
CNV
Moreover,
overexpression
positively
correlated
with
poor
clinical
outcomes.
The
GSEA
results
closely
tumor-promoting
biological
functions
also
negatively
associated
infiltration
levels
T
cells,
activated
NK
B
cells.
Most
immunomodulators
are
ENC1.
Further,
we
verified
inhibition
expression
suppressed
proliferation
migration
breast
cancer,
pancreatic
glioma
conclusion,
study
demonstrated
protumorigenic
Additionally,
tumor
microenvironment
features
immune
checkpoint
inhibitors
Overall,
could
serve
as
promising
potential
prognostic
biomarker
various
tumors.
Advanced Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 10, 2025
Abstract
Cancer
immunotherapy,
which
leverages
immune
system
components
to
treat
malignancies,
has
emerged
as
a
cornerstone
of
contemporary
therapeutic
strategies.
Yet,
critical
concerns
about
the
efficacy
and
safety
cancer
immunotherapies
remain
formidable.
Nanotechnology,
especially
polymeric
nanoparticles
(PNPs),
offers
unparalleled
flexibility
in
manipulation‐from
chemical
composition
physical
properties
precision
control
nanoassemblies.
PNPs
provide
an
optimal
platform
amplify
potency
minimize
systematic
toxicity
broad
spectrum
immunotherapeutic
modalities.
In
this
comprehensive
review,
basics
polymer
chemistry,
state‐of‐the‐art
designs
from
physicochemical
standpoint
for
encompassing
vaccines,
situ
vaccination,
adoptive
T‐cell
therapies,
tumor‐infiltrating
cell‐targeted
antibodies,
cytokine
therapies
are
delineated.
Each
immunotherapy
necessitates
distinctively
tailored
design
strategies
nanoplatforms.
The
extensive
applications
PNPs,
investigation
their
mechanisms
action
enhanced
particularly
focused
on.
profiles
clinical
research
progress
discussed.
Additionally,
forthcoming
developments
emergent
trends
nano‐immunotherapeutics
poised
transform
treatment
paradigms
into
clinics
explored.
Angewandte Chemie International Edition,
Journal Year:
2024,
Volume and Issue:
63(13)
Published: Jan. 12, 2024
Abstract
Immunotherapy
has
brought
a
new
dawn
for
human
being
to
defeat
cancer.
Although
existing
immunotherapy
regimens
(CAR‐T,
etc.)
have
made
breakthroughs
in
the
treatments
of
hematological
cancer
and
few
solid
tumors
such
as
melanoma,
therapeutic
efficacy
on
most
is
still
far
from
satisfactory.
In
recent
years,
researches
tumor
based
nanocatalytic
materials
are
under
rapid
development,
significant
progresses
been
made.
Nanocatalytic
medicine
demonstrated
be
capable
overcoming
limitations
current
clinicnal
by
using
toxic
chemodrugs,
exhibits
highly
attractive
advantages
over
traditional
therapies,
enhanced
sustained
durable
catalytic
activity,
remarkably
reduced
harmful
side‐effects
without
so
on.
Most
recently,
introduced
immune‐regulation
disease
treatments,
especially,
immunoactivation
therapies.
This
article
presents
immune‐response
activations
medicine‐initiated
chemical
reactions
immunotherapy,
elucidates
mechanism
medicines
regulating
anti‐tumor
immunity.
By
reviewing
research
progress
emerging
field,
this
review
will
further
highlight
great
potential
broad
prospects
nanocatalysis‐based
immune‐therapeutics.
Advanced Materials,
Journal Year:
2024,
Volume and Issue:
36(37)
Published: Feb. 9, 2024
Abstract
The
diagnosis
and
treatment
of
solid
tumors
have
undergone
significant
advancements
marked
by
a
trend
toward
increased
specificity
integration
imaging
therapeutic
functions.
multifaceted
nature
inorganic
oxide
nanomaterials
(IONs),
which
boast
optical,
magnetic,
ultrasonic,
biochemical
modulatory
properties,
makes
them
ideal
building
blocks
for
developing
multifunctional
nanoplatforms.
A
promising
class
materials
that
emerged
in
this
context
are
peptide‐functionalized
(PFIONs),
demonstrated
excellent
performance
therapy,
making
potential
candidates
advancing
tumor
treatment.
Owing
to
the
functionalities
peptides
targeting,
penetration,
responsiveness,
well‐designed
PFIONs
can
specifically
accumulate
release
or
agents
at
sites,
enabling
precise
effective
This
review
provides
an
overview
recent
advances
use
tumors,
highlighting
superiority
as
well
synergistic
Moreover,
discusses
challenges
prospects
depth,
aiming
promote
intersection
interdisciplinary
facilitate
their
clinical
translation
development
personalized
diagnostic
systems
optimizing
material
systems.
Nano Letters,
Journal Year:
2024,
Volume and Issue:
24(11), P. 3421 - 3431
Published: Feb. 20, 2024
Natural
killer
(NK)
cell-based
adoptive
immunotherapy
has
demonstrated
encouraging
therapeutic
effects
in
clinical
trials
for
hematological
cancers.
However,
the
effectiveness
of
treatment
solid
tumors
remains
a
challenge
due
to
insufficient
recruitment
and
infiltration
NK
cells
into
tumor
tissues.
Herein,
programmed
nanoremodeler
(DAS@P/H/pp)
is
designed
remodel
dense
physical
stromal
barriers
dysregulation
chemokine
environment
enhance
tumors.
The
DAS@P/H/pp
triggered
by
acidic
environment,
resulting
charge
reversal
subsequent
hyaluronidase
(HAase)
release.
HAase
effectively
degrades
extracellular
matrix,
promoting
delivery
immunoregulatory
molecules
chemotherapy
drugs
deep
In
mouse
models
pancreatic
cancer,
this
nanomediated
strategy
remodeling
microenvironment
significantly
boosts
NK92
their
cell-killing
capabilities
under
supervision
multiplexed
near-infrared-II
fluorescence.
ACS Applied Bio Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 10, 2025
Immunotherapy
is
a
cutting-edge
approach
that
leverages
sophisticated
technology
to
target
tumor-specific
antibodies
and
modulate
the
immune
system
eradicate
cancer
enhance
patients'
quality
of
life.
Bioinformatics
genetic
science
advancements
have
made
it
possible
diagnose
treat
patients
using
immunotherapy
technology.
However,
current
immunotherapies
against
limited
clinical
benefits
due
cancer-associated
antigens,
which
often
fail
interact
with
cells
exhibit
insufficient
therapeutic
targeting
unintended
side
effects.
To
surmount
this
challenge,
nanoparticle
systems
emerged
as
potential
strategy
for
transporting
immunotherapeutic
agents
activating
combat
tumors.
Consequently,
process
potentially
generates
an
antigen-specific
T
response
effectively
suppresses
growth.
Furthermore,
nanoplatforms
high
specificity,
efficacy,
diagnostic
potential,
imaging
capabilities,
making
them
promising
tools
treatment.
informative
paper
delves
into
various
available
immunotherapies,
including
CAR
therapy
checkpoint
blockade,
cytokines,
vaccines,
monoclonal
antibodies.
concept
theragnostic
nanotechnology,
integrates
diagnostics
more
personalized
treatment
therapy.
Additionally,
covers
different
nanocarrier
systems,
marketed
products,
trials,
regulatory
considerations,
future
prospects
immunotherapy.
